Astria Therapeutics Reports Positive Phase 1b/2 Trial Results for Navenibart in HAE Patients
Reuters
Nov 06, 2025
Astria <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 1b/2 Trial Results for Navenibart in HAE Patients
Astria Therapeutics Inc. has announced final positive results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in patients with hereditary angioedema $(HAE)$. The study, which enrolled 29 patients across 20 sites in six countries, demonstrated robust reduction in HAE attack rates and a favorable safety and tolerability profile. Both every three-month (Q3M) and every six-month (Q6M) dosing regimens were supported by the data. Clinically meaningful improvements in patient-reported quality of life were observed at six months. No serious treatment-emergent adverse events were reported. Topline results from the ongoing Phase 3 ALPHA-ORBIT trial are expected in early 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106100618) on November 06, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.